Sign in
AGRX Stock Price, Chart, Stats & News
Agile Therapeutics, Inc.
Save
10.43M
Market cap
–
Current P/E
–
Forward P/E
AGRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 54.18% |
Operating margin | -101.49% |
Pretax margin | -73.83% |
Net margin | -73.83% |
Effective tax rate | – |
ROA | -141.05% |
ROE | 132.32% |
D/E | -0.13x |
Interest coverage ratio | -14.01x |
AGRX valuation
P/E | – |
P/S | 0.53x |
P/B | -0.20x |
P/CF | -0.34x |
P/FCF | -1.09x |
P/OCF | -0.34x |
PEG | -0.00x |
EV multiple | -0.85x |
About
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually.
Similar securities
Based on sector and market capitalization
Report issue